Is there a 30 mg semaglutide dose, and what does it mean for your treatment?

Where does the 30 mg figure come from?

The short answer: not from any UK-licensed product. Semaglutide exists in the UK in two licensed forms for weight management, Wegovy as a weekly injection and, since 11 June 2026, Wegovy as a daily tablet. Neither reaches 30 mg at any stage of the approved schedule.

The figure most likely originates from two places. First, compounded semaglutide preparations (produced outside the licensed supply chain, often sold through social media or unverified websites) are sometimes offered at doses that don't correspond to any approved medicine. Second, some people conflate the oral tablet's milligram figures with the injection's, or misread research-stage dosing from early pharmaceutical studies that never translated into licensed products.

The MHRA has warned specifically about unlicensed weight-loss preparations sold online, including counterfeit pens and compounded products. If a seller is offering semaglutide at 30 mg, that is itself a red flag: the dose doesn't exist in any medicine the MHRA has approved, which means the product's contents, concentration and safety profile are unknown. You can check whether any pharmacy you're considering is GPhC-registered at the GPhC register.

Genuine semaglutide treatment follows an escalating schedule set out in the licensed prescribing information, slow titration exists for good clinical reasons, not as a formality.

What are the actual licensed doses of semaglutide for weight loss?

For the Wegovy injection, the approved starting dose is 0.25 mg weekly, moving through 0.5 mg, 1.0 mg, which has its own clinical considerations worth understanding, and 1.7 mg before reaching the standard 2.4 mg maintenance dose. If you'd like background on earlier steps in that ladder, the 2 mg dose stage page covers what that phase involves clinically.

The MHRA approved a higher 7.2 mg weekly dose on 12 January 2026, initially supplied as three 2.4 mg pens per week. On 14 April 2026 a dedicated single-dose 7.2 mg pen was approved for adults with a BMI of 30 or above. This is now the highest licensed injection dose and represents a meaningful step up in efficacy, trials reported around 20.7% average weight loss at 72 weeks. It's worth reading the full Wegovy dose guide for a complete picture of how the schedule works in practice.

For the oral Wegovy tablet, the approved schedule is 1.5 mg daily, rising through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. The tablet is taken first thing in the morning on an empty stomach, with a small amount of plain water, waiting at least 30 minutes before eating. No refrigeration needed, genuinely useful if your routine involves an early commute rather than a fridge to hand.

The NHS medicines page for semaglutide sets out the full prescribing information for patients in clear, verified language.

Why does the escalating dose schedule matter so much?

The titration isn't cautious for the sake of it. The most common side effects of semaglutide are gastrointestinal: nausea, loose stools, indigestion, occasional vomiting. Starting low and increasing slowly over several months gives the digestive system time to adjust, and most people find these effects settle considerably once they've been on a given dose for a few weeks.

Jumping to a much higher dose (particularly one outside the licensed range) removes that buffer entirely. With compounded preparations, there's a further problem: concentration errors. A small miscalculation in a compounded product's strength can mean a patient receives a fraction of the intended dose, or a multiple of it. The MHRA's concerns about these products are well-documented.

Side effects to take seriously include severe stomach pain that spreads to the back (which should prompt urgent medical attention given the known risk of pancreatitis with GLP-1 medicines, as highlighted in the MHRA Drug Safety Update from January 2026), signs of gallbladder problems, and symptoms of dehydration following prolonged vomiting or diarrhoea. Any suspected side effect from a licensed medicine can be reported via the Yellow Card scheme.

For context on how semaglutide's mechanism compares across doses, the semaglutide and insulin page covers the pharmacology in plain language.

What if you've already been on semaglutide and want to know about higher doses?

If you're established on treatment and wondering whether the 7.2 mg option is something to discuss, that conversation belongs with your prescriber. What's right depends on your current dose, how well you've tolerated it, your clinical picture and your weight-loss progress, not on what the highest available dose happens to be.

People who've been on semaglutide 2.4 mg weekly and are moving to the oral tablet may, depending on their clinical assessment, be able to start at the 25 mg tablet dose rather than re-titrating from 1.5 mg. Again, that's a prescriber decision, not a self-directed one.

For a broader look at how semaglutide treatment works from the start, the weight-loss treatment overview is a good place to get your bearings. And if you'd like to understand the cost side of things, Wegovy pricing sets out what private treatment typically involves financially.

If you'd like to talk through your specific situation with a GPhC-registered prescriber, you can speak to our prescribers through a free consultation, reviewed the same working day by a real clinician, not a queue for software.